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Cystic Fibrosis (CF) is the most common autosomal recessive lethal disorder among Cau-
casian populations. CF results from mutations and resulting dysfunction of the Cystic
FibrosisTransmembrane Conductance Regulator (CFTR). CFTR is a cyclic AMP-dependent
chloride channel that is localized to the apical membrane in epithelial cells where it plays
a key role in salt and water homeostasis. An intricate network of molecular chaperone
proteins regulates CFTR’s proper maturation and trafficking to the apical membrane. Under-
standing and manipulation of this network may lead to therapeutics for CF in cases where
mutant CFTR has aberrant trafficking.
Keywords: CFTR, chaperone, endoplasmic reticulum, ERAD, heat shock protein, phenylbutyrate
INTRODUCTION
The most common disease-causing mutation in cystic fibrosis
transmembrane conductance regulator (CFTR) is the deletion of
a single phenylalanine at position 508,∆F508-CFTR. This muta-
tion is present in one or both alleles of ∼90% of people with CF
(Riordan, 2008), making it an attractive target for therapeutics.
In contrast to wild type CFTR, which reaches the apical cell sur-
face after its N-linked oligosaccharides are modified in the Golgi
to an endoglycosidase H digestion-resistant form, ∆F508-CFTR
does not acquire endoglycosidase H resistance (Cheng et al., 1990).
These data suggested that ∆F508-CFTR is retained in the endo-
plasmic reticulum (ER; Kerem et al., 1989; Collins, 1992; Riordan,
1999; Bobadilla et al., 2002). Interestingly, ∆F508-CFTR appears
to retain some ability to transport chloride when in the ER (Pasyk
and Foskett, 1995), suggesting that the deletion of phenylalanine
interferes with proper biogenesis and promotes degradation of
the mutant protein (Ward and Kopito, 1994; Ward et al., 1995;
Okiyoneda et al., 2010).
Because∆F508-CFTR retains the ability to transport chloride,
it is widely hypothesized that correction of the mutant protein’s
trafficking would lead to functional CFTR at the apical cell sur-
face (Denning et al., 1992b; Li et al., 1993; Pasyk and Foskett,
1995). This premise was supported by early data from Drumm
et al. (1991), indicating that∆F508-CFTR was functional in Xeno-
pus oocytes, which are typically incubated at room temperature.
Studying mammalian cells, Denning et al. (1992a) found that
decreasing the cell incubation temperature led to an increase in
both expression and function of ∆F508-CFTR at the cell sur-
face. Overcoming this kinetic trafficking defect of ∆F508-CFTR
would be an important step in developing therapeutics for people
with CF.
CFTR BIOGENESIS
Proper biogenesis of the CFTR protein is not a trivial task. CFTR is
synthesized as a∼140 kDa protein (comprising 1480 amino acids)
and requires a number of processing steps to progress to a mature,
∼180 kDa form. The protein contains two nucleotide binding
domains (NBD1 and NBD2), two membrane-spanning domains
(MSD1 and MSD2), and an intervening regulatory domain (R;
Riordan et al., 1989). During translation, MSD1 is synthesized
first, followed by NBD1, R, MSD2, and finally NBD2; folding of
the nascent peptide appears to occurs both co-translationally and
post-translationally (Du et al., 2005; Kleizen et al., 2005).
F508 is located in NBD1, and while the crystal structures of
wild type and ∆F508 NBD1 are quite similar, deletion of F508
appears to cause NBD1 to have a more unfolded solution confor-
mation, as assessed by proton-deuterium exchange (Lewis et al.,
2005, 2010). Furthermore, deletion of F508 appears to destabilize a
critical interaction of NBD1/MSD2 interaction (Thibodeau et al.,
2005; Serohijos et al., 2008). Du et al. (2005) also suggested that
phenylalanine 508 provides an important interaction with NBD2
that assists in proper post-translational folding of this domain.
Together, these data suggest that newly synthesized ∆F508-CFTR
is less appropriately folded, and therefore more readily recognized
by ER quality control mechanisms and targeted for degradation.
Interestingly, Cui et al. (2007) found that a wild type CFTR
construct lacking the NBD2 domain escaped degradation and
trafficked to the cell membrane where it had similar stability to
full-length CFTR, but had a very low open probability. These data
suggest that, though important for CFTR activity, NBD2 is not
essential for CFTR biogenesis and exit from the ER. Consistent
with this notion, when this group introduced the ∆F508 muta-
tion into their NBD2-deficient construct, the resulting protein did
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not reach the plasma membrane, supporting the earlier hypothesis
that∆F508 impacts aspects of CFTR folding and biogenesis other
than the NBD1/NBD2 interaction.
MOLECULAR CHAPERONES
To better understand the difficulties of ∆F508-CFTR biogenesis,
it is important to examine the cellular context in which CFTR bio-
genesis occurs. The folding and trafficking environment, referred
to by Wang et al. (2006) as the “CFTR interactome,” contains
over 200 proteins that co-immunoprecipitate with either wild
type or ∆F508-CFTR in model systems. These co-precipitating
proteins, a number of which are implicated in proper folding,
trafficking, and function of CFTR, include a number of molecular
chaperone proteins. Molecular chaperones are proteins that aid
in the folding of other proteins, but do not become part of the
final product (Ellis, 1987). Instead, they promote self-assembly of
their client proteins and prevent non-productive folding. Histor-
ically, the functions of many molecular chaperones are defined
by their ability to assist in the refolding of denatured proteins,
such as luciferase, in vitro (Schroder et al., 1993; Barral et al.,
2004).
Molecular chaperones appear to interact with CFTR dur-
ing many stages of biogenesis. Nascent peptides of membrane
proteins, such as CFTR, are synthesized at the ER, where co-
translational folding occurs (Hartl, 1996). Because CFTR is
inserted into the ER membrane, its folding is monitored by chaper-
one proteins within both the ER and cytoplasm. If CFTR folding
is delayed or prolonged, interaction with molecular chaperones
(Loo et al., 1998; Meacham et al., 1999) can cause improperly
folded proteins to be transported back to the cytoplasm, where
they are targeted for degradation by the proteasome (reviewed in
Rivett, 1993). This process, known as ER-associated degradation
(ERAD), also involves a number of molecular chaperones. These
interactions and processes are discussed in detail below.
Appropriately folded CFTR exits the ER and is transported
to the Golgi where its N-linked glycosyl modification is further
processed into the mature form before trafficking to the apical cell
surface. The ∆F508-CFTR mutant is unable to reach the Golgi,
though it is able to transport chloride in reconstituted systems (Li
et al., 1993; Lukacs et al., 1993). A number of data suggest differing
and not mutually exclusive mechanisms by which∆F508-CFTR is
retained in the ER. One proposed mechanism suggests that recog-
nition of an ER exit sequence within NBD1 of the CFTR protein
by Coat Complex II (COP II) ER→Golgi transport machinery is
impaired in the ∆F508 protein (Chang et al., 1999; Wang et al.,
2004). Other works cite improper and/or more robust chaper-
one binding as the mechanism by which∆F508-CFTR is retained
in the ER (Pind et al., 1994; Wang et al., 2006). Hypothetically,
excessive chaperone binding could inhibit COP II’s access to the
ER exit motif within NBD1. To address this question, Wendeler
et al. (2007) affixed a strong ER exit signal to the wild type CFTR
protein. This signal did not disrupt protein localization or expres-
sion, but did enhance wild type CFTR maturation by two-fold.
In contrast, this ER exit signal did not enhance the maturation
of the ∆F508 protein, thereby contradicting the hypothesis that
a primary defect in the ER exit sequence is responsible for fail-
ure in ∆F508-CFTR trafficking. Instead, these data support the
hypothesis that molecular chaperone proteins may play a key role
in the quality control of wild type CFTR.
CFTR AND ERAD
Accumulated non-functional membrane or ER luminal proteins
can aggregate and interfere with the production or function of
other newly synthesized proteins, as well as cause an ER and/or
cellular stress response. To prevent this, aberrant proteins are rec-
ognized, shuttled out of the ER, and targeted for degradation by
ERAD.
Ciechanover and colleagues demonstrated that Hsc70, the con-
stitutively expressed 70 kDa heat shock protein, is required for the
ubiquitin-directed proteasome-mediated degradation of a num-
ber of cellular proteins (Bercovich et al., 1997); this ubiquitin-
proteasome pathway is also operative in ERAD. Hsc70 has a variety
of roles in the cell, including uncoating clathrin-coated pits and
promoting protein ubiquitination and both proteasomal and lyso-
somal degradation (Chiang et al., 1989; DeLuca-Flaherty et al.,
1990; Bercovich et al., 1997; Morgan et al., 2001). Because improp-
erly folded CFTR undergoes ubiquitination-mediated degradation
(Jensen et al., 1995; Ward et al., 1995), it was hypothesized that
Hsc70 promotes ERAD of ∆F508-CFTR. In fact, ∆F508-CFTR
associates more robustly with Hsc70 than wild type CFTR (Strick-
land et al., 1997; Meacham et al., 1999; Rubenstein and Zeitlin,
2000). Furthermore, pharmacologic disruption of Hsc70 binding
to either wild type or ∆F508-CFTR decreases CFTR ubiquitina-
tion (Fuller and Cuthbert, 2000), stabilizes the ER (immature band
B) form of CFTR (Fuller and Cuthbert, 2000), and can promote
CFTR maturation (Jiang et al., 1998).
Investigations in our group have focused on the mechanism
by which 4-phenylbutyrate (4PBA) enhances ∆F508-CFTR traf-
ficking (Rubenstein et al., 1997). We found that 4PBA decreased
Hsc70 mRNA and protein expression in CF epithelial cells, as
well as decreased recovery of ∆F508-CFTR when Hsc70 was
immunoprecipitated (Rubenstein and Zeitlin, 2000; Rubenstein
and Lyons, 2001). These data support the hypothesis that Hsc70
inhibits ∆F508-CFTR maturation, likely by promoting its ERAD
(see Figure 1).
Hsc70’s promotion of ERAD involves a co-chaperone known as
CHIP (C-terminus of Hsc70-interacting protein), an E3 ubiquitin
ligase (Wiederkehr et al., 2002; Murata et al., 2003). Meacham et al.
(2001) demonstrated that CHIP and Hsc70 cooperate to target
the immature (band B) form for ubiquitination and degradation;
overexpression of CHIP decreased whole cell and surface expres-
sion of CFTR. Simplistically, association of Hsc70 with a client
(like CFTR) would bring CHIP into proximity where it could cat-
alyze ubiquitination of the client. A more robust association of
Hsc70 with client, as was demonstrated by our group for ∆F508
vs. wild type CFTR (Rubenstein and Zeitlin, 2000), would portend
greater ubiquitination and likelihood for ERAD.
Additional co-chaperone proteins interact with the Hsc70/CHIP
complex to modulate their client interaction. HspBP1 binds Hsc70
and this binding decreases the ubiquitin ligase activity of CHIP
(Alberti et al., 2004). This, in turn, decreases the ubiquitin-
mediated degradation of CFTR and increased the steady-state
expression of either wild type or∆F508-CFTR in an in vitro assay.
Similarly, Bag-2 interacts with CHIP and inhibits its ubiquitin
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FIGURE 1 | Complexes implicated in ERAD.
ligase activity (Arndt et al., 2005). With regards to CFTR, increased
Bag-2 expression increases steady-state expression of both imma-
ture and mature CFTR in heterologous cells (Arndt et al., 2005).
Bag-2 appears to stabilize the NBD1 domain of CFTR and prevent
its aggregation while unfolded. Matsumura et al. (2011) performed
experiments in a cell-free system to discern the role of Hsc70 in
promoting biogenesis from its role in promoting ubiquitination.
Using a fragment of the Bag-1 protein to destabilize the interaction
between Hsc70 and CFTR led to a decrease in CFTR ubiquiti-
nation, but no effect on protein biogenesis (Matsumura et al.,
2011). Similarly, Meacham et al. (1999) found that the interaction
between Hsc70 and Hdj-2 promotes stabilization of a folding-
competent CFTR intermediate and prevents aggregation of NBD1,
while Zhang et al. (2006) also found that Hdj-2/Hsc70 promoted
stabilization of mature CFTR and prevented aggregation. Together,
these data suggest that Hsc70 and CHIP primarily cooperate to
promote ERAD of clients, and that this interaction can be modi-
fied by co-chaperones. In the case of∆F508-CFTR, a more robust
association with Hsc70/CHIP portents increased ERAD.
In addition to Hsc70, degradation of newly synthesized∆F508-
CFTR is also controlled by Derlin, an ER membrane-associated
complex comprised of RMA1 (an E3 ubiquitin ligase), Ubc6e (an
E2 ubiquitin-conjugating enzyme), and Derlin-1 (Younger et al.,
2006). Derlin-1 appears to retain ∆F508-CFTR at the ER mem-
brane and allow its recognition by Ubc6e and RMA1. Derlin-1
can interact with p97, the ATPase that extracts proteins from
the ER during ERAD, within a separate complex that also targets
CFTR for degradation (Sun et al., 2006). Derlin-1 overexpression
leads to decreased wild type and ∆F508-CFTR expression, while
RNAi-mediated depletion of Derlin-1 had the opposite effect.
Interestingly, the Derlin complex can ubiquitinate proteins co-
translationally (Younger et al., 2006), which is known to occur
for CFTR (Sato et al., 1998) while CHIP/Hsc70 primarily rec-
ognizes misfolded proteins post-translationally (Younger et al.,
2006). Derlin-1 degrades the CFTR fragment containing only
MSD1, but not longer forms of the protein, possibly because par-
tial CFTR folding prevents binding of Derlin-1 (Sun et al., 2006).
Together, these data suggest that Derlin and CHIP/Hsc70 have
complementary roles in surveillance of newly synthesized proteins
to prevent accumulation of misfolded proteins.
CFTR AND CHAPERONES IN THE CYTOPLASM
Folding of the cytosolic domains of CFTR requires coordinated
effort of heat shock proteins (Hsps), a large family of functionally
related chaperones that promote folding and prevent aggregation
of new proteins. ∆F508-CFTR demonstrates prolonged inter-
action with cytosolic Hsps (Yang et al., 1993; Loo et al., 1998;
Rubenstein and Zeitlin, 2000; Choo-Kang and Zeitlin, 2001), indi-
cating that these chaperones also represent potential therapeutic
targets in improving∆F508-CFTR trafficking.
Hsp70, the stress induced 70 kDa heat shock protein, and the
aforementioned Hsc70, are two extensively studied members of
this family. They are more than 85% identical on an amino acid
level, which has led many to hypothesize that Hsp70 and Hsc70
have similar functions. Interestingly, however, Hsp70 function
does not always overlap with Hsc70’s, and the two often have oppo-
site cellular effects (Gething and Sambrook, 1992; Goldfarb et al.,
2006). Experimentally, Hsc70 inhibition has been shown to lead
to an increase in Hsp70 expression (Aquino et al., 1996); this may
represent cellular stress, as Hsp70 expression is induced by such
stress (reviewed in Mayer and Bukau, 2005).
The exact role of Hsp70 in CFTR function and expression
remains controversial. Choo-Kang and Zeitlin examined the effect
of increased Hsp70 expression on CFTR in CF epithelial cells. In
contrast to previous data (Rubenstein and Zeitlin, 2000), their data
suggested that 4PBA increased Hsp70 expression and increased
Hsp70/CFTR interaction (Choo-Kang and Zeitlin, 2001). They
also found that overexpression of Hsp70 enhanced the interaction
between Hsp70 and∆F508-CFTR, which promoted∆F508-CFTR
maturation (see Figure 2). Suaud et al. (2011b) recently recon-
ciled these data and demonstrated that 4PBA causes a transient
increase in Hsp70 expression by a mechanism that involves the
STAT-3 transcription factor and its interacting protein, Elongator
Protein 2 (Elp2). This transient increase in Hsp70 expression with
4PBA is consistent with that suggested by gene expression profil-
ing experiments (Wright et al., 2004). Taken together, these data
support a model in which Hsp70 promotes proper trafficking of
∆F508-CFTR; this contrasts the role of its homolog, Hsc70, which,
as discussed above, appears to promote∆F508-CFTR degradation
by ERAD.
In contrast, Farinha et al. (2002) found no increase in either
wild type or ∆F508-CFTR maturation when both CFTR and
Hsp70 were overexpressed in Chinese Hamster Ovary (CHO) cells.
Instead, they saw increased wild type CFTR maturation only when
Hsp70’s co-chaperone, Hdj-1, was also overexpressed, but did not
see a similar increase in maturation of ∆F508-CFTR. They found
that Hsp70/Hdj-1 could slow the degradation rate of wild type
CFTR, but not the mutant protein, possibly because of the folded
state of ∆F508-CFTR. Farinha et al. also examined 4PBA treat-
ment of cells to determine if the effect was similar to the results
of their transient Hsp70/Hdj-1 overexpression. They observed a
more rapid degradation of ∆F508-CFTR with 4PBA treatment,
but no effect on wild type CFTR. This is contradictory to what was
seen in previous reports, which suggest 4PBA promotes ∆F508-
CFTR trafficking (Rubenstein et al., 1997; Choo-Kang and Zeitlin,
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FIGURE 2 | Chaperone proteins implicated in ∆F50S-CFTR biogenesis
and maturation.
2001; Suaud et al., 2011b). This apparent disparity may result from
the model systems under study. Farinha et al. used heterologous
CHO cells where CFTR (wild type or ∆F508) was overexpressed,
while others (Rubenstein et al., 1997; Choo-Kang and Zeitlin, 2001;
Suaud et al., 2011b) used IB3-1 CF bronchiolar epithelial cells
where∆F508-CFTR is endogenously expressed.
Another heat shock protein, Hsp90, also plays a key role in pro-
tein homeostasis and folding of a variety of proteins in a number
of organisms (reviewed in Balch et al., 2008; Hutt et al., 2009;
Powers et al., 2009). CFTR folding intermediates are stabilized by
binding to Hsp90, which prolongs their half-life and aids in their
trafficking and maturation (Loo et al., 1998; Fuller and Cuthbert,
2000; Wang et al., 2006). Hsp90 binding to client depends on its
ATPase activity, and both client binding and Hsp90 ATPase activ-
ity are enhanced by the presence of co-chaperones, such as Aha1
(Pearl and Prodromou, 2006). Recently,Aha1 was suggested to reg-
ulate CFTR interaction with Hsp90, leading to increased interest in
this co-chaperone (Wang et al., 2006). Sun et al. (2008) examined
chaperone binding of wild type and∆F508-CFTR and found that
both proteins interacted similarly with Hsp90. Interestingly, they
found that Aha1 interacted with∆F508-CFTR at almost twice the
affinity of wild type CFTR (Sun et al., 2008). They also expressed
CFTR fragments in an attempt to rescue ∆F508-CFTR traffick-
ing, as was reported in previous studies (Owsianik et al., 2003;
Clarke et al., 2004; Cormet-Boyaka et al., 2004). With one such
fragment of CFTR, they saw the predicted increase in ∆F508-
CFTR maturation and a corresponding decrease in Aha1 binding
to ∆F508-CFTR. These data suggest that Aha1 plays an impor-
tant role in the Hsp90-mediated stabilization of CFTR. Koulov
et al. (2010) recently extended these findings by demonstrating
that mutations introduced in both the N- and C-terminal struc-
tures of Aha1 decreased binding of Aha1 to Hsp90, which in turn
decreased the ATPase activity of Hsp90 and its ability to bind client
proteins. Taken together, these data suggest that Aha1 promotes
the binding of Hsp90 to client proteins by increasing the Hsp90’s
ATPase activity.
While initial studies using Hsp90 inhibitors, such as gel-
danamycin, suggested that Hsp90 promotes ∆F508-CFTR mat-
uration and trafficking (Loo et al., 1998; Wegele et al., 2004),
studies focused on Hsp90 and Aha1 suggest an alternate mecha-
nism (Wang et al., 2006; Koulov et al., 2010). It is likely that, similar
to Hsc70, the Hsp90/CFTR interaction is complex. Perhaps initial
binding between Hsp90 and CFTR lead to productive biogenesis.
However, if the interaction is prolonged by CFTR’s inability to
fold, CFTR is targeted for degradation instead.
While many studies focus on correcting the trafficking of
∆F508-CFTR to the apical cell surface, there is evidence that reg-
ulation of this mutant’s endocytic trafficking is also abnormal.
In fact, wild type CFTR is efficiently recycled back to the apical
cell membrane after endocytosis. In contrast, ∆F508-CFTR that
is delivered to the membrane using low temperature is removed
from the surface more rapidly and is recycled less efficiently than
the wild type CFTR (Cholon et al., 2009). These data suggest that
increasing the fraction of ∆F508-CFTR that arrives at the apical
cell surface, while important, may not be sufficient to increase
the functional expression of this mutant protein. Interestingly,
because Hsc70 is involved in endocytosis and the uncoating of
clathrin-coated vesicles (DeLuca-Flaherty et al., 1990; Morgan
et al., 2001), and for targeting proteins for degradation by the lyso-
somes (Gething and Sambrook, 1992), it seems likely that Hsc70
may also influence the stability of the wild type and mutant CFTR
proteins that are expressed on the apical cell surface. These data
also suggest that therapeutics which modulate the effect of Hsc70
on clathrin-mediated endocytosis may lead to increased apical
membrane stability of ∆F508-CFTR.
CFTR AND CHAPERONES IN THE ENDOPLASMIC RETICULUM
The role of ER luminal chaperones in CFTR biogenesis is less
well delineated. CFTR biogenesis appears influenced by additional
molecular chaperone proteins in the ER, including calreticulin and
calnexin. These proteins recognize terminal oligosaccharides on
proteins modified with high mannose N-linked glycosylation and
promote ER retention of “folding intermediates” until they either
fold properly or undergo ERAD. As such, Harada et al. (2006,
2007) found that CFTR expression and function were enhanced
by RNAi-mediated depletion of calreticulin in both cultured cells
and mouse models, suggesting that calreticulin negatively regu-
lates CFTR. Because previous reports indicated that curcumin,
a SERCA pump inhibitor, corrected ∆F508-CFTR trafficking to
the apical plasma membrane (Egan et al., 2004), Harada et al.
(2007) examined the mechanism by which this occurs. They found
that curcumin downregulates calreticulin expression, leading to
enhanced CFTR expression. Though curcumin alone could not
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activate ∆F508-CFTR in their experiments, in combination with
calreticulin knockdown they showed enhanced activity of mutant
CFTR, again consistent with calreticulin negatively regulating
CFTR.
Calnexin’s role in regulating CFTR biogenesis is less clear. Ini-
tial reports suggest that calnexin binds to immature CFTR, and
the interaction with∆F508-CFTR is prolonged, compared to wild
type CFTR (Pind et al., 1994). Based on these data, it is reason-
able to hypothesize that calnexin is responsible for ER retention of
∆F508-CFTR, and may therefore represent a viable target for ther-
apeutics to rescue∆F508-CFTR. However, recent studies suggest a
more complex picture of CFTR regulation by calnexin. One study
suggested that calnexin actually decreased ERAD of∆F508-CFTR
(Okiyoneda et al., 2004), and depletion of calnexin using RNAi
did not improve trafficking of newly synthesized ∆F508-CFTR
(Farinha and Amaral, 2005). While calnexin might not influence
CFTR trafficking as predicted, this study may have been limited by
incomplete calnexin depletion. To address this possibility, a follow-
up study examined CFTR trafficking in calnexin-deficient cells,
or cells containing calnexin mutant proteins (Okiyoneda et al.,
2008). One calnexin mutant, a truncated form that is exported
from the ER, was able to bind to∆F508-CFTR with similar affinity
to wild type. However, this mutant failed to increase the amount
of ∆F508-CFTR in the Golgi, suggesting that calnexin may not
be responsible for ER retention of ∆F508-CFTR. In complimen-
tary experiments, the group also employed wild type and calnexin
knockout murine embryonic fibroblasts (MEFs) to address caveats
of earlier RNAi experiments. They found that wild type CFTR
protein was decreased in calnexin knockout MEFs, compared to
MEFs containing wild type calnexin. Consistent with the RNAi
experiments, they found that neither ∆F508-CFTR trafficking
nor chloride transport was affected by calnexin knockout. These
data suggest that calnexin is not sufficient for ER retention and
degradation of the∆F508-CFTR protein. Instead, other ER chap-
erone proteins may represent a stronger therapeutic target for CF
patients.
Endoplasmic reticulum luminal chaperones involved in the
unfolded protein response (UPR) work closely with the ERAD
system. When protein folding in the ER is delayed, the UPR is
activated to reestablish homeostasis within the ER by increasing
the protein folding capacity of the cell and/or decreasing biosyn-
thesis (reviewed in Schroder and Kaufman, 2005). The UPR is
comprised of the regulator protein Grp78/BiP and a number of
signal transducers, including ATF6 and PERK (Bertolotti et al.,
2000; Lee, 2005). Under non-stress conditions, Grp78/BiP binds
ATF6 and maintains it in an inactive state. Under ER stress, such
as an excess of unfolded protein, Grp78/BiP preferentially binds to
the luminal unfolded protein, which releases and allows activation
of ATF6 and PERK, leading to initiation of the UPR.
Because ∆F508-CFTR is a misfolded protein, Kerbiriou et al.
hypothesized that ∆F508-CFTR-expressing cells would activate
the UPR. Using ATF6 and Grp78/BiP as markers of the UPR, they
found that protein levels of both Grp78/BiP and activated ATF6
were increased in∆F508-CFTR-containing cells (Kerbiriou et al.,
2007). Interestingly, RNAi-mediated depletion of ATF6, but not
Grp78/BiP, corrected ∆F508-CFTR trafficking, as evidenced by
increased ∆F508-CFTR-mediated chloride transport and surface
expression. These data suggest that the UPR pathway is involved
in the retention of ∆F508-CFTR in the ER, but that Grp78/BiP is
not involved directly in CFTR biogenesis. This is also consistent
with earlier data from Yang et al. (1993) and Pind et al. (1994),
which found no interaction between CFTR and Grp78/BiP, and
no effect of Grp78/BiP on the trafficking of∆F508-CFTR. In con-
trast to Kerbiriou et al. others have not found increased Grp78/BiP
expression in cells expressing ∆F508-CFTR (Nanua et al., 2006).
These seemingly contradictory findings may indicate a potentially
transient interaction between unfolded proteins and Grp78/BiP.
In addition, ERAD may be the predominant mechanism by which
the cell responds to unfolded CFTR, meaning that Grp78/BiP’s
role in the response to∆F508-CFTR is small, leading to a small or
negligible activation of the UPR. Based on these data, it remains
unclear what role the UPR plays in trafficking or internal retention
of ∆F508-CFTR.
Our group has recently focused on another ER chaperone and
its potential role in regulating CFTR trafficking. ERp29 (ER lumi-
nal protein of 29 kDa) is ubiquitously expressed, but is especially
prominent in brain and lung (Demmer et al., 1997). Its function is
not entirely clear, but is suggested to promote thyroglobulin secre-
tion and regulate assembly of connexin hemichannels (Sargsyan
et al., 2002; Hubbard et al., 2004; Baryshev et al., 2006; Das et al.,
2009), and it also seems to play a role in CFTR trafficking. Our
group recently demonstrated that 4PBA increased ERp29 mRNA
and protein expression (Suaud et al., 2011a). We also demon-
strated that overexpression of ERp29 in Xenopus oocytes and
mammalian cells increased the functional and surface expression
of wild type and ∆F508-CFTR, while RNAi-mediated depletion
of ERp29 decreased wild type CFTR in bronchial epithelial cells
(Suaud et al., 2011a). These data suggested that ERp29 protein acts
to promote biogenesis of both ∆F508 and wild type CFTR, and
is the first ER luminal protein described to have this role. While
additional studies are necessary, these data suggest an additional
mechanism by which 4PBA may correct∆F508-CFTR biogenesis
and trafficking.
MOLECULAR CHAPERONES AS PHARMACOLOGIC TARGETS
To improve the function of ∆F508-CFTR, it is important to con-
sider the many molecular chaperones in the CFTR“interactome”as
potential therapeutic targets. Though 4PBA is a prototype∆F508-
CFTR corrector, its effects are only partial. While most reports sug-
gest that 4PBA promotes ∆F508-CFTR trafficking by decreasing
Hsc70 and increasing Hsp70 (Rubenstein et al., 1997; Rubenstein
and Zeitlin, 1998, 2000; Choo-Kang and Zeitlin, 2001; Rubenstein
and Lyons, 2001; Suaud et al., 2011b), another found no 4PBA
effect on these chaperones or on ∆F508-CFTR (Farinha et al.,
2002). Early phase clinical trials showed a partial improvement
in CFTR-mediated chloride transport in ∆F508-CFTR homozy-
gous subjects with CF (Rubenstein and Zeitlin, 1998; Zeitlin et al.,
2002), but the amount of improvement suggested that more effica-
cious correctors would be necessary to achieve meaningful clinical
improvements.
In addition to 4PBA, a variety of Hsc70 inhibitors are being
examined as potential correctors of ∆F508-CFTR trafficking and
may also represent therapeutic targets for treatment of CF (see
Figure 3). Apoptazole is one such drug that interferes with Hsc70.
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Cho et al. (2011) found that apoptazole has the potential to pro-
mote∆F508-CFTR trafficking and activity. Apoptazole appears to
disrupt the ATPase activity of Hsc70 and decreases the ubiquitina-
tion of ∆F508-CFTR by blocking the interaction between Hsc70
and CHIP.
Matrine, a quinolizidine alkaloid, also downregulates Hsc70
expression, leading to an increase in ∆F508-CFTR protein levels
(Basile et al., 2012). It also allows ∆F508-CFTR to exit the ER
and localize to the plasma membrane, as evidenced by an increase
in interaction between ∆F508-CFTR and BAG3, a co-chaperone
located at the apical cell surface.
Deoxyspergualin is a drug that targets both Hsc70 and Hsp90
(Nadler et al., 1992; Nadeau et al., 1994), but has no apparent effect
on Hsp70. Jiang et al. (1998) found that deoxyspergualin treat-
ment increased CFTR activity in ∆F508-CFTR-expressing cells,
suggesting this drug may provide an alternate mechanism by which
to affect Hsc70 and indirectly increase ∆F508-CFTR trafficking.
Clinically, there are many potential problems with deoxysper-
gualin treatment, however, likely because Hsc70 and Hsp90 are
ubiquitously expressed proteins with many functions. Recently,
Norez et al. explored a potential solution to this problem by con-
structing a form of the molecule with an adjuvant. When they
generated a human serum albumin/deoxyspergualin construct,
they were able to deliver the drug at lower doses, with lower toxic-
ity, and achieve even better correction of∆F508-CFTR trafficking
than they saw with deoxyspergualin alone (Norez et al., 2008).
This is a promising method by which drugs could be delivered to
patients with lower toxicity.
Pharmacologic agents that specifically target Hsp90 are also
being studied to understand their effects on ∆F508-CFTR. Early
studies showed that geldanamycin, as well as other members of
the ansamycin family, target Hsp90, and disrupt binding to CFTR
(Loo et al., 1998). However, geldanamycin increased turnover
of CFTR by increasing CFTR’s susceptibility to ERAD. Based
on these data, it seems that geldanamycin would be detrimen-
tal, rather than helpful, in CF patients. However, more recent
data provided a completely different picture. Using an in vitro
system, Fuller and Cuthbert (2000) found that geldanamycin
interferes with degradation of ∆F508-CFTR by disrupting ubiq-
uitination. The caveat of this study is that it was conducted using
rabbit reticulocyte lysates, rather than cell or animal models. Fur-
ther investigation into geldanamycin or other Hsp90 inhibitors
is needed and would provide a more complete picture of the
role that these agents play in maturation of the mutant CFTR
protein.
The identification of ER luminal chaperones, such as ERp29,
that modulate CFTR and ∆F508-CFTR biogenesis is an exciting
new development. These chaperones may be useful targets for
development of novel∆F508-CFTR corrector strategies.
CONCLUSION
Patients currently receive therapeutics primarily aimed at treat-
ing symptoms of Cystic Fibrosis (CF; Ashlock and Olson, 2011;
Cuthbert, 2011), although the first mechanism-based therapy for
CF patients harboring a CFTR gating mutation like G551D was
recently approved. For most people with CF this is not a perma-
nent solution, thus new therapies that can target the underlying
pathology of the defect are needed. This is a difficult task, as
∆F508-CFTR correctors tested thus far have had only limited effi-
cacy (Rubenstein and Zeitlin, 1998), likely due to the complexities
of CFTR folding and trafficking. Targeting chaperone proteins
that influence CFTR, rather than CFTR itself holds promise for
success. Because of their ubiquitous expression and interactions
with so many cellular proteins, small changes in chaperone level
or function may have dramatic effects on client proteins, such as
CFTR.
FIGURE 3 | AF508-CFTR correctors and their molecular targets.
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It is important to keep in mind that the molecular chaperone
functions described here (ERAD, UPR, folding, etc.) are tightly
regulated and highly evolved to prevent the prolonged existence
of unfolded or improperly folded proteins. In order to overcome
the ∆F508-CFTR trafficking defect, it is necessary to find ways
to bypass and/or change the set point of these quality control
mechanisms. The system redundancy, highlighted by chaperone
proteins with similar or overlapping roles (e.g., Hsc70/CHIP and
Derlin), adds a level of security which is essential to the cell,
but difficult to overcome, from a scientific perspective. A very
delicate balance must be struck if a highly efficient therapeutic
agent is to be found. The compound must prolong the lifetime
of the misfolded ∆F508-CFTR protein, in order to allow proper
folding. However, increased half-life might also lead to increased
chaperone binding, which, as in the case of Hsp90, can counter-
productively force the cell to degrade misfolded proteins (Koulov
et al., 2010).
Because a large fraction of newly synthesized ∆F508-CFTR
is degraded by the ubiquitin-proteasome pathway, inhibition of
the proteasome inhibitors might seem like an attractive ther-
apeutic strategy. However, inhibiting proteasomal degradation
does not increase the functional ∆F508-CFTR at the apical cell
surface (Ward and Kopito, 1994; Ward et al., 1995). Instead,
inhibiting the proteasome led to intracellular accumulation of
ubiquitinated immature ∆F508-CFTR without increasing sur-
face expression and function. In addition, proteasomal inhibition
leads to increased cellular stress due to accumulation of mis-
folded proteins, which in turn induces expression of heat shock
proteins, such as Hsp70, Hsc70, and Hsp90 (Liao et al., 2006),
and may lead to cell apoptosis/death (Fribley et al., 2004; Park
et al., 2011). These data suggest that inhibition of the proteasome
is not a viable therapeutic option for correcting ∆F508-CFTR
trafficking.
Unfortunately, there are a number of difficulties that scientists
face in designing therapeutics to correct ∆F508-CFTR. Many of
the studies on CFTR and chaperones have been conducted using
overexpression systems. This, of course, is necessary for detec-
tion of the extremely low-level expression of∆F508-CFTR in cells
where the protein is not overexpressed. However, this overexpres-
sion makes interpretation of the results somewhat more difficult.
In addition, while often used non-epithelial cell models facilitate
the overexpression of wild type and∆F508-CFTR, non-epithelial
cells do not endogenously express CFTR, so their responses to
overexpression my not be physiologically relevant (as discussed
above, Farinha et al., 2002). Studies performed in these models
must be validated using epithelial cells.
CFTR expression varies between epithelial tissue types. Kalin et
al. examined samples from CF patients as well as healthy human
samples using immunohistochemistry. They found that the wild
type CFTR protein could be detected in sweat glands, lung epithe-
lia, and villi and goblet cells in the intestine (Kalin et al., 1999).
In contrast, ∆F508-CFTR could not be detected in sweat glands,
but expression in the lung and intestine were very similar to wild
type CFTR. While this study did not address the functional activ-
ity of ∆F508-CFTR in these tissues, these data suggest that CFTR
processing defects may be tissue type-specific and that ∆F508-
CFTR processing may affect some tissues more than others. Fur-
ther study of chaperone function in a range of epithelial tissues
is required to fully understand their role in CFTR trafficking and
activity.
Recent generation of novel animal models of CF, such as the
ferret and pig, and their disease pathology is of great benefit to
the advancement of this field as a whole (reviewed in Fisher et al.,
2011) and (Keiser and Engelhardt, 2011). While the role of chap-
erones in CFTR trafficking have yet to be investigated in these
models, future interrogations of epithelial cells from these models
will undoubtedly yield a great deal of insights into both underlying
physiology and therapeutic approaches.
Many chaperone proteins are upregulated in response to cel-
lular stress, which may result from overexpression of exogenous
proteins or increased abundance of misfolded proteins in the ER.
Overexpressing ∆F508-CFTR may lead to a specific activation
of proteins needed to fold the mutant, or instead cause a global
upregulation of chaperone proteins involved in ERAD or the UPR,
simply by increasing cellular stress. Studies examining overexpres-
sion of both wild type and ∆F508-CFTR lend credence to the
hypothesis that the response is specific to the mutant protein, but
this is still a concern that needs to be addressed when designing
therapeutics.
Many pharmacologic agents that correct ∆F508-CFTR traf-
ficking do so by an as yet unknown mechanism. Though many
chaperones have been extensively studied, there are still aspects of
our understanding that are lacking. This is evidenced by studies
with seemingly contradictory data, discussed above. As an addi-
tional caveat, chaperone proteins have many targets and interact
with an abundance of proteins in response to cellular stress. While
changes in chaperone expression may positively influence∆F508-
CFTR expression, the effects on other important protein pathways
could have unforeseen negative consequences. The use of these
pharmacologic agents must be understood in the context of these
other roles for chaperones within the cell. Building an even greater
knowledge base of molecular chaperones and∆F508-CFTR, in the
context of the CFTR “interactome,” will help to fill in the gaps and
lead to a better understanding of the pharmacologic agents, as well
as the proteins that they target.
Finally,∆F508-CFTR interacts with many other proteins dur-
ing its lifetime, and it may not be possible to design a single
molecule to correct all its potentially problematic interactions.
Instead, a combination of therapeutics may be more appropriate
and effective. Targeting multiple chaperones may allow therapies
to avoid the trap of decreasing a single molecular chaperone pro-
tein too much. Small changes in multiple chaperones may provide
the balance needed to prolong the life of ∆F508-CFTR enough
to allow proper folding, but not so much that it is recognized
by ERAD or the UPR. These sorts of small changes to multi-
ple chaperones may also help create therapies with less toxic side
effects.
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